The Bracco Group, established in 1927, is a multinational healthcare group, which operates in 90 countries worldwide.
Bracco extended the range of its offering over the years, thanks to acquisitions and strong innovation capabilities, entering the Magnetic Resonance imaging (MRI) market with ProHance® (gadoteridol) injection, 279.3 mg/mL and MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL, consolidating its leadership in X-Ray/CT with Isovue® (iopamidol injection) and entering the Nuclear Medicine segment, with a leading position in fast growing niche areas of Positron Emission Tomography (PET), Cardiology, and Hepatobiliary Imaging. And it continues to devote considerable effort and substantial resources to create and develop innovative products and solutions addressing unmet or poorly met medical needs.
Since the Nineties, the Company has begun a globalization process. Bracco Imaging today operates in over 90 markets worldwide, either directly or indirectly through subsidiaries, joint ventures, license and distribution partnership agreements.
Moreover, Bracco Imaging's portfolio was broadened in 2008 with the acquisition of E-Z-EM, Inc., a major manufacturer of contrast media and medical devices for gastrointestinal (GI) radiology.
Bracco Imaging wants to consolidate its position as an open source provider of diagnostic imaging solutions aimed at providing quality solutions in terms of diagnostic efficacy, customer safety and cost effectiveness.